kratom and semaglutide How Much Does Cost With/Without Insurance? FDA warning against Kratom strengthened

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Primary Endpoint: Weight Loss at 72 Weeks The results were striking and clinically significant: Zepbound Group: Participants achieved an average weight reduction of 20.2% at 72 weeks Wegovy Group: Participants achieved an average weight reduction of 13.7% at 72 weeks Relative Difference: Zepbound provided 47% greater relative weight loss compared to Wegovy To put this in practical terms: A patient weighing 250 pounds could expect to lose approximately 50 pounds with Zepbound versus 34 pounds with Wegovy over the same timeframe

The phase 2 and phase 3 trials focused primarily on total body weight reduction

Mettl17, a regulator of mitochondrial ribosomal RNA modifications, is required for the translation of mitochondrial coding genes